Elanco Health Health Incorporated (NYSE: ELAN) has received an average “Hold” recommendation from twelve analysts currently covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company. The average 1-year target price among analysts who updated their stock coverage last year was $ 29.19.

Some equity research analysts recently commented on ELAN stocks. TheStreet cuts Elanco Animal Health from a “c” rating to a “d” rating in a research report on Friday, November 6th. Barclays lowered Elanco Animal Health from its “overweight” rating to a “low weight” rating and reduced its stock price target from $ 35.00 to $ 25.00 in a research note Monday, November 9th. Morgan Stanley raised its Elanco Animal Health target price from $ 31.00 to $ 41.00 and gave the company a “overweight” rating in a research note on Monday, November 23rd. Citigroup Inc. Principal Minimum Coupon 3% Protected Base Russell raised Elanco Animal Health’s target price from $ 32.00 to $ 35.00 and gave the company a “buy” rating on research notes Tuesday, November 17th. Finally, Argus dropped Elanco Animal Health from a “buy” rating to a “hold” rating in research records, Wednesday, December 9th.
ELAN opened at a price of $ 29.07 on Thursday. The stock has a fifty-day moving average of $ 30.38 and a two-day moving average of $ 29.07. The company has a current ratio of 1.75, a fast ratio of 0.90 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $ 13.72 billion, a profit-to-profit ratio of -51.00, a price-to-earnings-ratio of 4.13 and a beta of 0.86. Elanco Animal Health has a 12-month low of $ 15.17 and a 12-month high of $ 34.09.

(Advertising)

The oil company is making a living in the trillion-dollar trading world

In related news, major shareholder Aktiengesellschaft Bayer sold 54,500,000 shares of business shares in a transaction on Thursday, December 3rd. The stock traded at an average price of $ 29.84, with a total transaction of $ 1,626,280,000.00. The transaction is disclosed in a legal submission to the Securities & Exchange Commission, available at this hyperlink. 0.12% of the shares owned by internally.

Some institutional investors and hedge funds have recently bought and sold the shares. Mackenzie Financial Corp rose its position in Elanco Animal Health by 20.1% in the 4th quarter. Mackenzie Financial Corp currently owns 14,544 shares of the company worth $ 446,000 after buying an additional 2,436 shares in the last quarter. Aviva PLC rose to prominence in Elanco Animal Health 24.9% in the 4th quarter. Aviva PLC now owns 1,138,197 corporate shares worth $ 34,906,000 after buying an additional 226,644 shares in the last quarter. Panagora Asset Management Inc. increased its position in Elanco Animal Health by 61.2% in the 4th quarter. Panagora Asset Management Inc. currently owns 20,180 shares of the company’s stock worth $ 619,000 after buying an additional 7,659 shares last quarter. Oxford Financial Group Ltd. increased its position in Elanco Animal Health by 72.0% during the 4th quarter. Oxford Financial Group Ltd. currently owns 15,615 shares of the company worth $ 479,000 after buying an additional 6,538 shares in the last quarter. Finally, KBC Group NV raised its position in Elanco Animal Health by 5.3% in the 4th quarter. KBC Group NV now owns 105,716 shares of the company worth $ 3,242,000 after buying an additional 5,290 shares in the last quarter. Institutional investors own 86.83% of the company’s stock.
Profile of Elanco Animal Health Company

Elanco Health Health Incorporated, an animal healthcare company, innovates, develops, manufactures, and markets products for companion animals and food. It offers animal disease prevention products, such as parasites and vaccine products that protect livestock from fleas, lice, and fleas; companion animal therapy for pain, osteoarthritis, ear infections, cardiovascular, and dermatological indications in fangs and cats; vaccines, antibiotics, parasites, and other products used for poultry production and aquaculture, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and various vaccines, antibiotics, implants, parasites, and other products used for the production of ruminants and pigs.

Article Upload: Advantages and disadvantages of average dollar costs

Elanco Animal Health Analyst Recommendations (NYSE: ELAN)

This instant news alert was created by narrative science technology and financial data from MarketBeat to provide reporters with the fastest and most accurate information. This story was reviewed by MarketBeat’s editorial team before being published. Post a comment or comment about this story to [email protected]

12 Marijuana Shares Available Now

There are now more than 50 publicly traded companies operating in the cannabis industry. Most of these companies do not directly grow and sell their own marijuana, but it can be very beneficial as more countries are legalizing the sale of marijuana. Some of these marijuana stocks are media companies. Other people learn about the personal use of marijuana. But others provide tools and software for marijuana farmers. As more cannabis companies file IPOs and enter the stock market, investors will find it difficult to know which marijuana stocks will benefit from the cannabis explosion.

Customers have begun digging into the company, checking their finances, business model and long-term growth prospects. He knows that some “marijuana stocks” are just empty shell shells worth a penny stock, but he also knows that there are some legitimate and growing companies that really benefit from the green effort. As a group, they have added 10 different cannabis stocks to their playlists and are actively investing. More than 1,400 MarketBeat customers now join the most popular cannabis companies.

This slide show lists 12 pot shares that MarketBeat customers have added to their playlists and actively monitors.

See “12 Shares of Marijuana Available Now”.

LEAVE A REPLY